Adria Hasan , Naushad Ahmad Khan , Shahab Uddin , Abdul Q. Khan , Martin Steinhoff
{"title":"Deregulated transcription factors in the emerging cancer hallmarks","authors":"Adria Hasan , Naushad Ahmad Khan , Shahab Uddin , Abdul Q. Khan , Martin Steinhoff","doi":"10.1016/j.semcancer.2023.12.001","DOIUrl":null,"url":null,"abstract":"<div><p>Cancer progression is a multifaceted process that entails several stages and demands the persistent expression or activation of transcription factors (TFs) to facilitate growth and survival. TFs are a cluster of proteins with DNA-binding domains that attach to promoter or enhancer DNA strands to start the transcription of genes by collaborating with RNA polymerase and other supporting proteins. They are generally acknowledged as the major regulatory molecules that coordinate biological homeostasis and the appropriate functioning of cellular components, subsequently contributing to human physiology. TFs proteins are crucial for controlling transcription during the embryonic stage and development, and the stability of different cell types depends on how they function in different cell types. The development and progression of cancer cells and tumors might be triggered by any anomaly in transcription factor function. It has long been acknowledged that cancer development is accompanied by the dysregulated activity of TF alterations which might result in faulty gene expression. Recent studies have suggested that dysregulated transcription factors play a major role in developing various human malignancies by altering and rewiring metabolic processes, modifying the immune response, and triggering oncogenic signaling cascades. This review emphasizes the interplay between TFs involved in metabolic and epigenetic reprogramming, evading immune attacks, cellular senescence, and the maintenance of cancer stemness in cancerous cells. The insights presented herein will facilitate the development of innovative therapeutic modalities to tackle the dysregulated transcription factors underlying cancer.</p></div>","PeriodicalId":21594,"journal":{"name":"Seminars in cancer biology","volume":null,"pages":null},"PeriodicalIF":12.1000,"publicationDate":"2023-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1044579X2300158X/pdfft?md5=8d19160c82caf1bfc8b7e2414e89ebac&pid=1-s2.0-S1044579X2300158X-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in cancer biology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1044579X2300158X","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Cancer progression is a multifaceted process that entails several stages and demands the persistent expression or activation of transcription factors (TFs) to facilitate growth and survival. TFs are a cluster of proteins with DNA-binding domains that attach to promoter or enhancer DNA strands to start the transcription of genes by collaborating with RNA polymerase and other supporting proteins. They are generally acknowledged as the major regulatory molecules that coordinate biological homeostasis and the appropriate functioning of cellular components, subsequently contributing to human physiology. TFs proteins are crucial for controlling transcription during the embryonic stage and development, and the stability of different cell types depends on how they function in different cell types. The development and progression of cancer cells and tumors might be triggered by any anomaly in transcription factor function. It has long been acknowledged that cancer development is accompanied by the dysregulated activity of TF alterations which might result in faulty gene expression. Recent studies have suggested that dysregulated transcription factors play a major role in developing various human malignancies by altering and rewiring metabolic processes, modifying the immune response, and triggering oncogenic signaling cascades. This review emphasizes the interplay between TFs involved in metabolic and epigenetic reprogramming, evading immune attacks, cellular senescence, and the maintenance of cancer stemness in cancerous cells. The insights presented herein will facilitate the development of innovative therapeutic modalities to tackle the dysregulated transcription factors underlying cancer.
癌症进展是一个涉及多个阶段的多方面过程,需要转录因子(TFs)的持续表达或激活,以促进生长和存活。转录因子是一组具有 DNA 结合域的蛋白质,它们附着在启动子或增强子 DNA 链上,通过与 RNA 聚合酶和其他辅助蛋白质合作启动基因转录。它们是公认的主要调控分子,可协调生物平衡和细胞成分的正常功能,进而促进人体生理机能。TFs 蛋白在胚胎阶段和发育过程中对转录的控制至关重要,不同细胞类型的稳定性取决于它们在不同细胞类型中的功能。转录因子功能的任何异常都可能引发癌细胞和肿瘤的发展和恶化。人们早已认识到,癌症的发展伴随着转录因子活性失调的改变,这可能会导致基因表达错误。最近的研究表明,转录因子失调通过改变和重构新陈代谢过程、改变免疫反应和触发致癌信号级联,在各种人类恶性肿瘤的发展中扮演着重要角色。这篇综述强调了参与代谢和表观遗传重编程、逃避免疫攻击、细胞衰老以及维持癌细胞中癌症干性的转录因子之间的相互作用。本文提出的见解将有助于开发创新的治疗模式,以解决癌症背后的转录因子失调问题。
期刊介绍:
Seminars in Cancer Biology (YSCBI) is a specialized review journal that focuses on the field of molecular oncology. Its primary objective is to keep scientists up-to-date with the latest developments in this field.
The journal adopts a thematic approach, dedicating each issue to an important topic of interest to cancer biologists. These topics cover a range of research areas, including the underlying genetic and molecular causes of cellular transformation and cancer, as well as the molecular basis of potential therapies.
To ensure the highest quality and expertise, every issue is supervised by a guest editor or editors who are internationally recognized experts in the respective field. Each issue features approximately eight to twelve authoritative invited reviews that cover various aspects of the chosen subject area.
The ultimate goal of each issue of YSCBI is to offer a cohesive, easily comprehensible, and engaging overview of the selected topic. The journal strives to provide scientists with a coordinated and lively examination of the latest developments in the field of molecular oncology.